Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy – an ancillary study of the SAKK 09/10 randomized clinical trial

Autor: Dal Pra, A, Ghadjar, P, Hayoz, S, Liu, V Y T, Spratt, D E, Thompson, D J S, Davicioni, E, Huang, H-C, Zhao, X, Liu, Y, Schär, C, Gut, P, Plasswilm, L, Hölscher, T, Polat, B, Hildebrandt, G, Müller, A-C, Pollack, A, Thalmann, G N, Zwahlen, D, Aebersold, D M

Publikováno v: Dal Pra, A; Ghadjar, P; Hayoz, S; Liu, V Y T; Spratt, D E; Thompson, D J S; Davicioni, E; Huang, H-C; Zhao, X; Liu, Y; Schär, C; Gut, P; Plasswilm, L; Hölscher, T; Polat, B; Hildebrandt, G; Müller, A-C; Pollack, A; Thalmann, G N; Zwahlen, D; ... (2022). Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy-An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial. Annals of oncology, 33(9), pp. 950-958. Elsevier 10.1016/j.annonc.2022.05.007

The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase III trial of dose-escalated salvage radiotherapy (SRT) after radical p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5192fd9d39303f62c68bbee115821cf
https://doi.org/10.1016/j.annonc.2022.05.007

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

MO-0544 4pi-IMRT based path-finding for dynamic trajectory radiotherapy

Autor: Mackeprang, P., Bertholet, J., Mueller, S., Guyer, G., Loebner, H. A., Frei, D., Volken, W., Eliçin, O., Aebersold, D. M., Fix, M. K., Manser, P.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::690deefb5348d4bde464cc9b6f461a34

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Autor: Panje, C M, Lupatsch, J E, Barbier, M, Pardo, E, Lorez, M, Dedes, K J, Aebersold, D M, Plasswilm, L, Gautschi, O, Schwenkglenks, Matthias

BACKGROUND Consolidation immunotherapy with the programmed death ligand 1 (PD-L1) inhibitor durvalumab improves survival in patients with stage III non-small-cell lung cancer responding to radiochemotherapy. The aim of this study was to assess the co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b1b2ac792cbfc0e85dd09492b5f508

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.